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Abstract: Dystonia is an involuntary movement involving twisting and turning of agonist and 
antagonist muscles. Cervical dystonia is isolated to neck musculature. Botulinum toxin type A 
is a safe and effective treatment of this disabling and often painful syndrome. Three forms of 
botulinum toxin type A are available worldwide to treat patients with cervical dystonia. This is 
a review of the studies of botulinum toxin type A to treat cervical dystonia.
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Introduction
Dystonia is an involuntary movement involving twisting and turning of agonist 
and antagonist muscles.1 Cervical dystonia (CD) is a dystonic disorder of the neck 
musculature, characterized by tilting, turning of the neck.2 CD is often painful and 
leads to disability interfering with working, driving, reading and other activities of 
daily living.3 In a 1988 retrospective chart review, the prevalence of CD is estimated 
to be 9/100,000.4 More recently, the Dystonia Medical Research Foundation estimates 
that 250,000 people suffer from CD but many more are suspected to be undiagnosed 
and/or untreated (http://www.dystonia-foundation.org/).
Idiopathic CD generally presents slowly over several years in mid to late adulthood 
but the age of onset may vary widely. Secondary causes of CD include tardive dystonia 
after exposure to dopamine blocking medications and post-traumatic dystonia.5 While 
CD presents with an involuntary tilt or turn of the neck muscles, the patients also 
frequently experience pain. Regardless of the etiology, CD often results in permanent 
disability due to decreased range of motion, involuntary movements and intractable 
pain.6 All forms of CD can beneﬁ  t from selective injection of botulinum toxin into 
overactive muscles of the neck.
Before the introduction of botulinum toxin (BoNT) to treat CD, therapy was 
limited to oral medication and surgery. Oral medications included anticholinergics, 
benzodiazepines, and antispasticity medications.7 Oral medications are often 
associated with side effects of sedation, dry mouth, and withdrawal symptoms. 
In the past, surgery for CD included selective denervation and myotomies,8–10 but 
more recently have been replaced with deep brain stimulation (DBS) for refractory 
cases.11 In 2007 the experienced Canadian group published a series of 10 patients 
with medical refractory CD who improved on with stimulation of bilateral globus 
pallidus internus.11 In a larger study, 40 patients with primary segmental or generalized 
dystonia treated with DBS were randomly assigned to receive either neurostimula-
tion or sham stimulation for 3 months. After 3 months signiﬁ  cant improvement in 
the Burke-Fahn-Marsden Dystonia Rating Scale was noted in the stimulations group 
compared to the sham stimulations group (p  0.001). Adverse events included lead 
infection, lead dislodgment and dysarthria.12Biologics: Targets & Therapy 2009:3 2
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The introduction of botulinum toxin type A (BoNT-A) 
in 1989 in the US dramatically improved the care of patients 
with CD. The addition of botulinum toxin type B (BoNT-B) 
in 2000 as an alternative treatment to type BoNT-A further 
expanded the resources to treat this disabling disease.13,14 
In 2008 the Therapeutics and Technology Assessment 
Subcommittee of the American Academy of Neurology 
concluded that BoNT is established as safe and effective for 
the treatment of CD based on seven Class I studies.15 Based 
upon a review of the literature, the expert group recom-
mended that BoNT injection should be offered as a treatment 
option to patients with CD and that BoNT is probably more 
efﬁ  cacious and better tolerated in patients with CD than 
treatment with trihexyphenidyl (see Table 1). The reports 
also noted that there were no data to compare BoNT with 
any form of surgical treatment of CD.15
Serotypes of botulinum toxin
The bacterium, Clostridium botulinum produces seven 
immunologically distinct serotypes but only serotype A16–18 
and B14,19 have been used routinely in clinical practice to 
treat patients with CD. Serotype F has limited availability 
in Japan.20,21 Worldwide there are three forms of botulinum 
toxin type A (BTX-A): BOTOX® (Allergan, Irvine, CA), 
Dysport® (Ipsen), and Xeomin® (Merz Pharmaceuticals 
GmbH, Frankfurt, Germany) commercially available. The 
different brands vary by commercial processing, strength and 
amounts of protein. Each of the type A serotypes is a unique 
form of botulinum toxin. Of the non A serotypes, serotype B 
is available as botulinum toxin type B (BoNT-B) (marketed 
as Myobloc™ in the US and NeuroBloc® elsewhere). The 
development of new formulations or different serotypes of 
botulinum toxin is an active research area and more options 
for patients may be forthcoming.
Each of the seven serotypes of botulinum toxin is 
synthesized as a single-chain polypeptide with a molecular 
weight of 150 kDa.22 To activate the toxin, the disulﬁ  de 
bond holding the heavy chain and light chain together 
must be cleaved,23 followed by internalization of the 
light chain into the cytosol. The entire process is called 
“chemodenervation”.24,25
The pharmacologic activity of the speciﬁ  c light chain 
of the serotype is speciﬁ  c to which proteins it interacts with 
at the neuromuscular junction.26 Regardless of the type of 
serotype used, once the toxin is recognized at the presynaptic 
terminal and internalized by endocytosis and translocated to 
the cytosol. Subsequently at the presynaptic nerve terminal 
the light chain catalyses a zinc-dependent protein cleavage. 
The result deactivates components of the “SNARE” (soluble 
N-ethyl-maleimide sensitive factor attachment protein 
Receptor complex).26–28
Different components of the SNARE are required for 
successful release of the acetylcholine vesicle.26 Of the 
seven serotypes, there are differences at the level of acceptor 
binding and substrate interference in the SNARE complex. 
The light chain of each serotype acts at a distinct site on one 
or more of the proteins required for vesicle release. The light 
chain of BTX type A and E targets the cytoplasmic protein 
SNAP-25 while the light chain of serotype B toxin spe-
ciﬁ  cally targets VAMP/synaptobrevin.29,30,31 Even when the 
same protein is affected, the different serotypes (for example 
A and E) affect it at a different sites of the same protein. 
Clinically, treatment with BoNT-A relaxes muscles, but the 
dose required and side effects may vary by formulation.
The bacterial proteins in BoNTs have the potential to 
elicit immunologic responses when injected in humans. 
Neither the incidence rates for neutralizing antibodies nor 
the clinical meaningfulness of the presence of antibodies 
have been clearly established. The exact cause of antibody 
formation to BoNT in a particular patient is unknown 
but studies have linked the development of neutralizing 
antibodies to the formulations and its protein load, the dose 
used per treatment cycle, the total cumulative dose given to 
a patient and the frequency of repeated injections.17,32,33
Antibodies to BoNT have been measured by determining 
the clinic response in the patient. For example in the Frontalis 
Antibody Test (FTAT) or Unilateral Brow Injection (UBI) 
either the Frontalis or corrugator muscle are injected with 
a small amount of BoNT-A capable of eliciting a clinical 
response.32,34–36 Others have used the change in a Compound 
Motor Action Potential (CMPA) after treatment of the 
extensor digitorum brevis (EDB) in the foot with toxin.37 
Still others have used the Mouse Protection Assay (MPA) 
to determine the ability of antibodies in the patient to pro-
tect a toxin naïve mouse when exposed to a fatal dose of 
toxin.34,38,39 Regardless of the method, the secondary devel-
opment of antibodies in patients with a previous response to 
BoNT remains a concern for patients and physicians using 
this effective form of treatment. Once neutralizing antibod-
ies develop, a sustained beneﬁ  t to that serotype is rarely 
experienced by the patient.40
Early experience with BoNT-A (Dysport and BOTOX®) 
in CD suggests that the incidence of neutralizing antibodies 
ranges from 4% to 17%, depending on the formulation 
used.26,41 A new formulation of BOTOX® with a lower protein 
load has been in use since 1998.38 A prospective longitudinal Biologics: Targets & Therapy 2009:3 3
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study in 326 subjects with CD found the incidence of 
neutralizing antibodies to be 1.2%.33 Only 4 of 326 subjects 
tested positive for antibodies in the MPA; 3 of these subjects 
stopped responding clinically to BoNT-A (of whom one also 
showed clinical resistance in the FTAT) and one continued 
to respond. The formulation for Dysport® has not been 
reported to have changed. Limited studies with Dysport® have 
reported its incidence of neutralizing antibody formation to 
be between 0% and 3%.26 No clinical immunogenicity data 
have been published to date for Xeomin®.43
Botulinum toxin 
for treatment of CD
Because of the existence of three formulations of BoNT-A, 
all different formulations, trade names will be used in this 
section to discern which formulations are being discussed.
Studies of botulinum toxin type A 
(formulated as BOTOX®)
BOTOX® (sold in the US since the late 1980s) was pioneered 
by Dr Allan Scott, a pediatric ophthalmologist, for the treat-
ment of strabismus.44 Originally labeled Oculinum, once 
marketed by Allergan, Inc., the formulation quickly became 
known by its trade name, BOTOX®. Off-label treatment of 
patients with CD with BOTOX® started in the late 1980s and 
continued until FDA approval in 2000. Despite the accep-
tance of the safety and efﬁ  cacy of BOTOX®, only a limited 
number of large multi-center trials in the treatment of CD 
with BOTOX® have been published (see Table 1).
The largest trial of BoNT-A (formulated as BOTOX®) 
studied 170 subjects with CD at 21 centers is published 
in abstract form and the package insert.41 Prior BOTOX® 
responders who continued to receive a good response to injec-
tions were included in the study. A unique outcome measure, 
the Cervical Dystonia Severity Scale (CDSS), similar to a 
large protractor, measured the change in turn, tilt or shift 
after treatment.45 Subjects were treated with BOTOX® and 
followed for 12 weeks with the CDSS. At 12 weeks after the 
ﬁ  rst injection, the patients who responded to the BOTOX® 
and demonstrated 20° or greater change in head position 
from normal were randomized to receive either BOTOX® 
or placebo. The difference between the BTX-A treated and 
placebo-treated groups on the CDSS was 1.03 to 3.13 (corre-
sponding to an improvement of approximately 5.15° to 10.65° 
in head position) (p  0.046) at weeks 2, 4, 6, 8, and 10. In 
addition, a Physician’s Global Assessment score was statis-
tically signiﬁ  cant at weeks 2, 4, 6, and 8. According to the 
package insert, the common adverse events for the BTX-A 
treated patients were upper respiratory infections, neck pain, 
back pain, dysphagia, and rhinitis. This is the largest reported 
multi-center, double-blind, placebo-controlled trial with 
BOTOX® in patients with CD.2,41,46,47 However, this study 
has only been reported in abstract form and the information 
listed above is available in the package insert approved by 
the US Food and Drug Administration.41
Older studies noted improvement in patients with CD 
treated with BOTOX®. In 1990, Jankovic et al reported 
follow-up of 202 out of 232 subjects with medically 
intractable CD for at least 3 months and up to 4 years, 
during which time they received 1074 injections of BTX-A.18 
Seventy-one percent reported improvement of symptoms and, 
in those with pain, 76% had almost complete relief of their 
pain. Side effects included mild dysphagia and neck weak-
ness. In series of smaller studies, Gelb et al administered 
injections to 20 patients with CD and demonstrated subjective 
improvement in 80% of subjects.48 Blackie et al reported 
the results of 19 patients who participated in a double-blind 
placebo-controlled trial of BTX-A in patients with CD, 
demonstrating a mean improvement in neck posture in 83% 
if the treatment periods had a mean duration of 12 weeks.25 
A recent long-term study47 also found that efﬁ  cacy (measured 
as global response) and duration of effect tend to increase 
over time. In a longitudinal study of dose consistency, 
Brashear et al48 found that dose and dose interval were 
consistent over a 2-year period.49
Studies of CD with botulinum toxin 
type A (formulated as Dysport®)
Botulinum toxin type A (Dysport®) is currently available 
outside the US and is labeled in European countries for 
treatment of CD.50,51 Efﬁ  cacy and safety of Dysport® for 
treatment of CD has been studied in ﬁ  xed dose52 and variable 
dose34 protocols.
In a large European multi-center study, 75 patients 
were randomly assigned to receive treatment with placebo 
or total doses of 250, 500, and 1000 Dysport® units (U) 
divided between two muscles, the splenius capitus and the 
contralateral sternocleidomastoid. Those treated with 500 or 
10000 U demonstrated signiﬁ  cant changes in the modiﬁ  ed 
Tsui score at week 4 versus placebo (p  0.05). Additionally 
positive dose-response relations were found for the degree 
of subjective patient report, duration of improvement, and 
improvement on a clinical global rating scale. A dose-
response relationship for treatment-related adverse events 
occurred with increasing doses. The authors suggested that 
a starting dose of 500 U of Dysport® should be used to lower Biologics: Targets & Therapy 2009:3 5
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the risk of neck muscle weakness and voice changes and to 
assure some efﬁ  cacy. The starting recommendations were 
500 U with titration upwards to 1000 U as needed.52
In the first multi-center, double-blind, randomized, 
controlled trial in the US, 80 patients with CD were randomly 
assigned to receive one treatment with Dysport® (500 U) or 
placebo.34 Over the 20-week trial, Dysport® demonstrated 
more improvement in the total Toronto Western Spasmodic 
Torticollis Rating Scale score than placebo at weeks 4,8, 
and 12. The median duration of response to Dysport®  was 
18.5 weeks. Side effects were generally similar in the two 
treatment groups; only blurred vision and weakness occurred 
signiﬁ  cantly more often with Dysport®.
In the dose-ranging study increasing doses of Dysport® 
resulted in improved duration of response but with increasing 
overall incidence of adverse events (AEs) (37%, 65%, and 
83% with 250, 500, and 1000 U, respectively).49 The most 
common AEs were dry mouth (21%, 18%, and 33% with 250, 
500, and 1000 U, respectively), neck muscle weakness (11%, 
12%, and 56% with 250, 500 and 1000 U, respectively), and 
dysphagia (21%, 29%, and 39% with 250, 500, and 1000 U, 
respectively).52
A study comparing trihexyphenidyl tablets versus injec-
tions of Dysport® in 64 patients with CD demonstrated 
signiﬁ  cant changes in of favor Dysport® on the disability 
section of the Toronto Western Spasmodic Torticollis 
Rating Scale (TWSTRS-Disability) (primary outcome), Tsui 
Scale, and the General Health Perception Subscale.53 More 
patients treated with Dysport had an improvement of at least 
3 points on the TWSTRS-Disability subscale and on the Tsui 
Scale than those treated with oral medication. In addition, 
adverse effects were signiﬁ  cantly less frequent in the Dysport 
group than the trihexyphenidyl treated group.53
Those physicians who have both BOTOX® and Dysport®  
available in their countries need to have a clear understanding 
of the differences in dosing. While these are both from the 
type A serotype, they are formulated differently and human 
studies demonstrate different doses needed for treatment. In a 
comparative, double-blind study of Dysport® and BOTOX®, 
patients with prior exposure to BOTOX® demonstrated that 
a Dysport® dose of 3 times the BOTOX® dose demonstrated 
similar efﬁ  cacy with no different in safety proﬁ  les (58% 
of the Dysport®  group reporting adverse events versus 
69% of the BOTOX® group [p = 0.85]).54 The duration of 
effect, assessed by time to pretreatment, was also similar 
(mean [SD]; Dysport®, 83.9 [13.6] days; BOTOX®, 80.7 
[14.4] days; p = 0.85).55 Of note is that the large clinical 
trial (which led to labeling of BOTOX® for CD in the US) 
had a average dose of 232 U. BOTOX® and Dysport® are 
different medications and are dosed differently. The differ-
ence between the recommended dose of 500 U of Dysport®  
by Wissel et al51 and the average dose of BOTOX® of 232 U 
listed in the package insert should be clearly understood by 
treating physicians who have access to both drugs.
Studies of BoNT-A (formulated 
as Xeomin®)
Xeomin® is a newly formulated puriﬁ  ed, freeze-dried BTX-A 
reportedly free of complexing proteins. No placebo-controlled 
trial of Xeomin® in patients with CD has been performed. 
However, in a head to head comparative trial, of BOTOX® 
and Xeomin®, both drugs were comparable in the treat-
ment of patients with CD.43 A total of 466 patients with CD 
were recruited from 51 European centers to participate in 
the non-inferiority study. Using the TWSTRS total rating 
scale as the primary outcome, the study demonstrated no 
difference in efﬁ  cacy between the two drugs on day 28 after 
injection. At baseline, patients in both groups had a median 
TWSTRS Severity score of 18 points and scores improved 
by a median of 11 points in both groups at day 28 after 
treatment. Both treatment groups improved compared to 
baseline (p value for change in TWSTRS Severity score was 
p  0.0001).43 The authors propose that the clinical effects of 
the two drugs were comparable in the patients studied.
Technique of botulinum toxin 
injections for CD
The technique of botulinum toxin injection remains both 
a science and an art. An understanding of the anatomy of 
the neck remains essential. The interaction of the neck 
musculature and head movement determines which muscles 
are involved in the primary problem movement in the indi-
vidual patients (see Table 2 for a list of muscles typically 
involved in these neck movements). Moreover, the patient 
may have a compensatory movement used to ally some of the 
discomfort of CD. Many practioners use a series of clinical 
observations and palpation to determine which muscles to 
treat and how much BoNT-A to use in a particular patient.2
The use of electromyography remains controversial. 
While those who inject BTX-A for CD may not consis-
tently use electromyography, Comella et al reported a 
signiﬁ  cantly greater magnitude of improvement in those in 
whom the neck muscles treated were selected by clinical 
and electromyographic guidance than those in whom only 
clinical examination was used.56 In the Therapeutics and 
Technology Assessment of the American Academy of Biologics: Targets & Therapy 2009:3 6
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Neurology, the authors concluded that the use of EMG 
remained controversial.15
Regardless of which formulation is used to treat patients, 
the practioner should understand the muscles involved in the 
primary head movements of tilt, turn, anterocollis, retrocollis, 
and shoulder elevation (see Table 2 for a list of common 
muscles treated with BoNT-A). Focusing on the primary 
movement provides the patient with relief while limiting the 
side effects from treating non-involved muscles.
Summary
BoNT-A is a safe and effective therapy for CD. Three 
formulations are available worldwide, but as of 2008 only 
BOTOX® is available in the US. The dosages between the 
formulations of Dysport and BOTOX® are different and the 
dosage of Xeomin® in preliminary studies mirrors BOTOX® 
dosing. The use of BoNT-A has dramatically improved treat-
ments for patients with CD. Physicians treating patients with 
CD will need to be attentive to the burgeoning literature on 
all three forms of BoNT-A, including variations in dosing, 
efﬁ  cacy, and side effects.
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